Sridhar Nimmagadda
Johns Hopkins University
117 Papers
506 Citations
Sridhar Nimmagadda is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Biodistribution. The author has an hindex of 34, co-authored 95 publications. Previous affiliations of Sridhar Nimmagadda include University of Freiburg & Johns Hopkins University School of Medicine.
Chat about Author
Papers
•Journal Article
[177Lu]XYIMSR-01, a Theranostic for Targeting Carbonic Anhydrase IX
Il Minn,Hye Soo Lee,Soo Min Koo,Hye-Hyun Ahn,Steven P. Rowe,Michael A. Gorin,Polina Sysa-Shah,Jae Sul,Yuchuan Wang,Sangeeta Ray Banerjee,Ronnie C. Mease,Sridhar Nimmagadda,Mohamad E. Allaf,Martin G. Pomper,Xing Yang +14 more
TL;DR: A dual-motif, LMW inhibitor of CAIX, [177Lu]XYIMSR-01 is a promising theranostic agent targeting CAIX-expressing tumors, especially ccRCC in the context of local and metastatic disease.
5
Patent
Theranostic imaging agents and methods of use
Martin G. Pomper,Zaver M. Bhujwalla,Zhihang Chen,Cong Li,Sridhar Nimmagadda,Marie-France Penet,Sangeeta Ray +6 more
- 30 Mar 2012
TL;DR: In this paper, targeted nanoplex molecules which carry multimodal imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes are used for theranostic imaging of cells and diseases, including, for example, various cancers, including metastatic prostate cancer.
5
Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with ( 64 Cu)AMD3100 Positron
Sridhar Nimmagadda,Mrudula Pullambhatla,Kristie Stone,Gilbert Green,Zaver M. Bhujwalla,Martin G. Pomper +5 more
- 01 Jan 2010
TL;DR: The findings show the feasibility of imaging CXCR4 by positron emission tomography using a clinically approved agent as a molecular scaffold, and the ability of [ 64 Cu] AMD3100 to image CX CR4 expression.
5
Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging
TL;DR: In this paper , the authors used radiolabeled CAR-T cells with 89 Zirconium-oxine ( 89 Zr-oxide) and compared their product attributes with non-labeled CART cells.
PET/MRI and Bioluminescent Imaging Identify Hypoxia as a Cause of Programmed Cell Death Ligand 1 Image Heterogeneity.
Katie M. Parkins,Balaji Krishnamachary,Desmond Jacob,Samata Kakkad,Meiyappan Solaiyappan,Akhilesh Mishra,Yelena Mironchik,Marie-France Penet,Michael T. McMahon,Philipp Knopf,Bernd J. Pichler,Sridhar Nimmagadda,Zaver M. Bhujwalla +12 more
TL;DR: In this paper , the authors examined the association between hypoxia and programmed cell death ligand 1 (PD-L1) expression using bioluminescence imaging (BLI) and PET/MRI in a syngeneic mouse model of triple-negative breast cancer (TNBC).
4